Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (127)

« Back to Publications

ntifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders.

Champaneria R. et al, (2026), Cochrane Database Syst Rev, 2

Recombinant von Willebrand Factor (vonicog alfa) reduces platelet inhibition caused by antiplatelet drugs and has potential as an acute haemostatic agent.

Desborough MJR. et al, (2026), Haematologica

Can drug-induced platelet dysfunction be reversed?

Maynard S. et al, (2026), Res Pract Thromb Haemost, 10

Baseline serum ferritin predicts myocardial iron uptake following intravenous iron therapy - a hypothesis-generating study.

Nunez J. et al, (2025), Eur J Heart Fail, 27, 2352 - 2356

BO matching for platelet transfusions for prevention or treatment of bleeding: A systematic review with meta-analysis.

Cain L. et al, (2025), Transfus Med Rev

Hypercoagulation After Hospital Discharge in Acute Severe Ulcerative Colitis: A Prospective Study.

Griffiths BJ. et al, (2025), Clin Gastroenterol Hepatol, 23, 1798 - 1807.e5

Platelets sequester extracellular DNA, capturing tumor-derived and free fetal DNA.

Murphy L. et al, (2025), Science, 389

Carbon footprint of a sample of clinical trials for people with neurological disorders: cross-sectional analysis.

Cranley D. et al, (2025), BMJ Open, 15

Blood transfusion strategies for major bleeding in trauma.

Brunskill SJ. et al, (2025), Cochrane Database Syst Rev, 4

Myocardial iron intake following intravenous iron therapy with ferric carboxymaltose is sustained at 1 year despite recurrence of iron deficiency.

Piechnik SK. et al, (2025), Br J Haematol, 206, 349 - 352

Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial.

TREATT Trial Investigators ., (2025), Lancet Haematol, 12, e14 - e22

Baseline ferritin predicts myocardial iron uptake following intravenous iron therapy- a hypothesis generating study

Nunez J. et al, (2025)

Intravenous iron therapy results in rapid and sustained rise in myocardial iron content through a novel pathway.

Vera-Aviles M. et al, (2024), Eur Heart J, 45, 4497 - 4508

Transfusion Camp: The UK experience and its value in improving knowledge of transfusion medicine among postgraduate trainees.

Aggarwal A. et al, (2024), Transfus Med, 34, 450 - 454

Desmopressin for prevention of bleeding for thrombocytopenic, critically ill patients undergoing invasive procedures: A randomised, double-blind, placebo-controlled feasibility trial.

Desborough MJR. et al, (2024), EJHaem, 5, 772 - 777

Load More

1
2
3
4
5
6
7
...
»